PharmaEssentia Corporation
6446
Ранг среди акций
#1448
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Цена акции
$35.96
Рыночная капитализация
$14.87B
Изменение (1 день)
-0.85%
Изменение (1 год)
138.77%
Страна
TW
Торговля PharmaEssentia Corporation (6446)
Категория
Healthcare
История цены акций PharmaEssentia Corporation (6446)
Наивысшая цена закрытия: $37.51 2026-10-01
Наименьшая цена закрытия: $4.95 2014-03-01
Наименьшая цена закрытия: $4.95 2014-03-01
История цены акций PharmaEssentia Corporation с 2014 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | 78.21% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $162.50 | 21.52% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $223.41 | 30.46% |
CH
|
|
| $18.43 | -4.03% |
IN
|
